IDrug: A web-accessible and interactive drug discovery and design platform

Journal of Cheminformatics

Volumn 6, Issue 1, 2014, Pages

  Wang, Xia ^a   Chen, Haipeng ^a   Yang, Feng ^a   Gong, Jiayu ^a   Li, Shiliang ^a   Pei, Jianfeng ^b   Liu, Xiaofeng ^a   Jiang, Hualiang ^a   Lai, Luhua ^b   Li, Honglin ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

3D similarity calculation; Cavity detection; Online drug design platform; Pharmacophore search; Target prediction

Indexed keywords

EID: 84902272377     PISSN: None     EISSN: 17582946     Source Type: Journal    
DOI: 10.1186/1758-2946-6-28     Document Type: Article

References (61)

1. Recent advances in computer-aided drug design. Song CM, Lim SJ, Tong JC, Brief Bioinform 2009 10 579 591
2. The many roles of computation in drug discovery. Jorgensen WL, Science 2004 303 1813 1818
3. Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems. Kellenberger E, Foata N, Rognan D, J Chem Inf Model 2008 48 1014 1025
4. A computational approach to finding novel targets for existing drugs. Li YY, An J, Jones SJ, PLoS Comput Biol 2011 7 1002139
5. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. Nettles JH, Jenkins JL, Bender A, Deng Z, Davies JW, Glick M, J Med Chem 2006 49 6802 6810
6. Drug target identification using side-effect similarity. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P, Science 2008 321 263 266
7. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening. Liu X, Jiang H, Li H, J Chem Inf Model 2011 51 2372 2385
8. LigBuilder 2: a practical de novo drug design approach. Yuan Y, Pei J, Lai L, J Chem Inf Model 2011 51 1083 1091
9. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Wolber G, Langer T, J Chem Inf Model 2005 45 160 169
10. ShaEP: molecular overlay based on shape and electrostatic potential. Vainio MJ, Puranen JS, Johnson MS, J Chem Inf Model 2009 49 492 502
11. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Kurogi Y, Guner OF, Curr Med Chem 2001 8 1035 1055
12. The errors of our ways: taking account of error in computer-aided drug design to build confidence intervals for our next 25 years. Stouch TR, J Comput Aided Mol Des 2012 26 125 134
13. Computer-aided drug design platform using PyMOL. Lill MA, Danielson ML, J Comput Aided Mol Des 2011 25 13 19
14. TarFisDock: a web server for identifying drug targets with docking approach. Li H, Gao Z, Kang L, Zhang H, Yang K, Yu K, Luo X, Zhu W, Chen K, Shen J, Wang X, Jiang H, Nucleic Acids Res 2006 34 219 W224
15. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Gong J, Cai C, Liu X, Ku X, Jiang H, Gao D, Li H, Bioinformatics 2013 29 1827 1829
16. ZINCPharmer: pharmacophore search of the ZINC database. Koes DR, Camacho CJ, Nucleic Acids Res 2012 40 409 W414
17. fpocket: online tools for protein ensemble pocket detection and tracking. Schmidtke P, Le Guilloux V, Maupetit J, Tuffery P, Nucleic Acids Res 2010 38 582 W589
18. Some thoughts on the "A" in computer-aided molecular design. Rarey M, J Comput Aided Mol Des 2012 26 113 114
19. e-LEA3D: a computational-aided drug design web server. Douguet D, Nucleic Acids Res 2010 38 615 W621
20. Sanjeevini: a freely accessible web-server for target directed lead molecule discovery. Jayaram B, Singh T, Mukherjee G, Mathur A, Shekhar S, Shekhar V, BMC Bioinforma 2012 13 Suppl 17 7
21. Pocket v. 2: further developments on receptor-based pharmacophore modeling. Chen J, Lai L, J Chem Inf Model 2006 46 2684 2691
22. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, Zheng S, Li Z, Li H, Jiang H, Nucleic Acids Res 2010 38 609 W614
23. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. Lu W, Liu X, Cao X, Xue M, Liu K, Zhao Z, Shen X, Jiang H, Xu Y, Huang J, Li H, J Med Chem 2011 54 3564 3574
24. Discovery of novel selective inhibitors for EGFR-T790M/L858R. Bai F, Liu H, Tong L, Zhou W, Liu L, Zhao Z, Liu X, Jiang H, Wang X, Xie H, Bioorg Med Chem Lett 2012 22 1365 1370
25. Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit. O'Boyle NM, Morley C, Hutchison GR, Chem Cent J 2008 2 5
26. Open Babel: an open chemical toolbox. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR, J Cheminform 2011 3 1 14
27. Enhanced CACTVS browser of the Open NCI Database. Ihlenfeldt W-D, Voigt JH, Bienfait B, Oellien F, Nicklaus MC, J Chem Inf Comput Sci 2002 42 46 57
28. ZINC-a free database of commercially available compounds for virtual screening. Irwin JJ, Shoichet BK, J Chem Inf Model 2005 45 177 182
29. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M, Nucleic Acids Res 2008 36 901 D906
30. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK, Nucleic Acids Res 2007 35 198 D201
31. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. Wang R, Fang X, Lu Y, Wang S, J Med Chem 2004 47 2977 2980
32. PDTD: a web-accessible protein database for drug target identification. Gao Z, Li H, Zhang H, Liu X, Kang L, Luo X, Zhu W, Chen K, Wang X, Jiang H, BMC Bioinforma 2008 9 104
33. Binding site detection and druggability prediction of protein targets for structure- based drug design. Yuan Y, Pei J, Lai L, Curr Pharm Des 2013 19 2326 2333
34. Strategy for discovering chemical inhibitors of human cyclophilin A: focused library design, virtual screening, chemical synthesis and bioassay. Li J, Zhang J, Chen J, Luo X, Zhu W, Shen J, Liu H, Shen X, Jiang H, J Comb Chem 2006 8 326 337
35. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. Wei D, Jiang X, Zhou L, Chen J, Chen Z, He C, Yang K, Liu Y, Pei J, Lai L, J Med Chem 2008 51 7882 7888
36. Discovery and SAR of thiazolidine-2, 4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. Liu X, Xie H, Luo C, Tong L, Wang Y, Peng T, Ding J, Jiang H, Li H, J Med Chem 2010 53 2661 2665
37. Acenaphtho [1, 2-b] pyrrole-Based selective fibroblast growth factor receptors 1 (FGFR1) Inhibitors: design, synthesis, and biological activity. Chen Z, Wang X, Zhu W, Cao X, Tong L, Li H, Xie H, Xu Y, Tan S, Kuang D, J Med Chem 2011 54 3732 3745
38. Cyndi: a multi-objective evolution algorithm based method for bioactive molecular conformational generation. Liu X, Bai F, Ouyang S, Wang X, Li H, Jiang H, BMC Bioinforma 2009 10 101
39. Bioactive conformational generation of small molecules: a comparative analysis between force-field and multiple empirical criteria based methods. Bai F, Liu X, Li J, Zhang H, Jiang H, Wang X, Li H, BMC Bioinforma 2010 11 545
40. The protein data bank. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE, Nucleic Acids Res 2000 28 235 242
41. Discovery of Pteridin-7 (8 H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) Kinase T790M/L858R mutant. Zhou W, Liu X, Tu Z, Zhang L, Ku X, Bai F, Zhao Z, Xu Y, Ding K, Li H, J Med Chem 2013 56 7821 7837
42. Sci Tegic Accelrys Inc., the MDL Drug Data Report (MDDR). Symyx Technologies. MDL drug data report, Database is available at http://www.accelrys.com/
43. New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. Dong G, Wang S, Miao Z, Yao J, Zhang Y, Guo Z, Zhang W, Sheng C, J Med Chem 2012 55 7593 7613
44. Maximum unbiased validation (MUV) data sets for virtual screening based on PubChem bioactivity data. Rohrer SG, Baumann K, J Chem Inf Model 2009 49 169 184
45. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK, J Med Chem 2012 55 6582 6594
46. Towards more accurate pharmacophore modeling: multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. Zou J, Xie H-Z, Yang S-Y, Chen J-J, Ren J-X, Wei Y-Q, J Mol Graph Model 2008 27 430 438
47. Comparative analysis of pharmacophore screening tools. Sanders MP, Barbosa AJ, Zarzycka B, Nicolaes GA, Klomp JP, de Vlieg J, Del Rio A, J Chem Inf Model 2012 52 1607 1620
48. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. de Medina P, Favre G, Poirot M, Curr Med Chem Anticancer Agents 2004 4 491 508
49. Identification and pharmacological characterization of cholesterol-5, 6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. De Medina P, Paillasse MR, Segala G, Poirot M, Silvente-Poirot S, Proc Natl Acad Sci 2010 107 13520 13525
50. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Ramaswamy B, Lu Y, Teng K-y, Nuovo G, Li X, Shapiro CL, Majumder S, Cancer Res 2012 72 5048 5059
51. The effect of toremifene therapy on serum immunoglobulin levels in breast cancer. Paavonen T, Aronen H, PyrhÖNen S, Hajba A, Andersson L, Apmis 1991 99 849 853
52. Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal. Favoni RE, de Cupis A, Trends Pharmacol Sci 1998 19 406 415
53. Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens. Santner SJ, Santen RJ, J Steroid Biochem Mol Biol 1993 45 383 390
54. Effects of estrogen and tamoxifen on the regulation of dihydrofolate reductase gene expression in a human breast cancer cell line. Levine RM, Rubalcaba E, Lippman ME, Cowan KH, Cancer Res 1985 45 1644 1650
55. Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Nuwaysir EF, Daggett DA, Jordan VC, Pitot HC, Cancer Res 1996 56 3704 3710
56. The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by tamoxifen. Ritchie GA, Recent Results Cancer Res 1980 71 96 101
57. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, Fraga C, Morton CL, Howard-Williams EL, Potter PM, J Mol Biol 2005 352 165 177
58. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A, Biochem Pharmacol 1995 50 723 726
59. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Nilsson UW, Garvin S, Dabrosin C, Breast Cancer Res Ttreat 2007 102 253 261
60. Leu-enkephalin, tamoxifen and ethanol interactions: effects on motility and hepatic ethanol metabolizing enzymes. Messiha FS, Gen Pharmacol 1990 21 45 48
61. Antagonistic action of estrogens, flutamide, and human growth hormone on androgen-induced changes in the activities of some enzymes of hepatic steroid metabolism in the rat. Lax E, Rumstadt F, Plasczyk H, Peetz A, Schriefers H, Endocrinology 1983 113 1043 1055